Charles Schwab
MTCR

Charles Schwab’s Metacrine, Inc. Common Stock MTCR Stock Holding History

Charles Schwab’s Portfolio MTCR Stock Details MTCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-13,800
Closed -$86K – 3581
2021
Q1 		$86K Hold
13,800
– – ﹤0.01% 3391
2020
Q4 		$109K Buy
+13,800
New +$127K ﹤0.01% 3315

Other funds holding MTCR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Charles Schwab's MTCR Position: Q2 2021 in Review

Charles Schwab sold out of Metacrine, Inc. Common Stock (MTCR) in Q2 2021, closing a stake of 13,800 shares — an estimated $86K sold.

Charles Schwab first reported a position in MTCR in Q4 2020 and held it in 2 quarters. The position peaked at $109K in Q4 2020. 42 funds tracked by Wall St. Rank hold MTCR as of Q2 2021.

  • Charles Schwab reported no remaining Metacrine, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Charles Schwab sold 13,800 Metacrine, Inc. Common Stock shares in Q2 2021, an estimated $86K.
  • Charles Schwab first reported a position in Metacrine, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • Charles Schwab's Metacrine, Inc. Common Stock position peaked at $109K in Q4 2020.
  • 42 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q2 2021.

Based on Charles Schwab's 13F filing for Q2 2021, filed 16 Aug 2021.